Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | PDE6A | P16499 | 1/20 | 0.54 |
| ▸ | PDE6G | P18545 | 1/20 | 0.54 |
| ▸ | PDE6B | P35913 | 1/20 | 0.54 |
| ▸ | PDE6C | P51160 | 1/20 | 0.54 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.54 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698791 | 1.00 | PDE5A (0.61) | PDE5AMEN1KMT2APOLBPDE6D | |
| SCHEMBL7698798 | 1.00 | PDE5A (0.61) | PDE5AMEN1KMT2APOLBPDE6D | |
| SCHEMBL7439361 | 0.98 | PDE5A (0.61) | PDE5AMEN1KMT2APOLBPDE6D | |
| SCHEMBL7440907 | 0.87 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7690896 | 0.87 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7690901 | 0.87 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL1343834 | 0.85 | PDE5A (0.69) | PDE5AKMT2A | |
| SCHEMBL1343838 | 0.85 | PDE5A (0.69) | PDE5AKMT2A | |
| SCHEMBL1343837 | 0.85 | PDE5A (0.69) | PDE5AKMT2A | |
| SCHEMBL7443998 | 0.85 | KMT2A (0.72) | PDE5AMEN1KMT2APOLBPDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | PDE5A 4371/4885MEN1 756/4885KMT2A 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.